Related Experiment Video
Updated: Jul 30, 2025
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Guillain-Barré Syndrome Following the BNT162b2 mRNA COVID-19 Vaccine
Hussein A Algahtani1, Bader H Shirah2, Yazeed K Albeladi3
1Neurology Section, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia; King Abdullah International Medical Research Center, Jeddah, Saudi Arabia; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Purpose:
The onset of the COVID-19 (SARS-CoV-2) pandemic in December 2019 created the need for multiple scientific research activities and clinical trials in an attempt to find solutions to mitigate the impact of the virus. One of the important tools to combat the virus is the development of vaccination programs. All types of vaccines have been associated with a mild to severe risk of neurological adverse events. One of these severe adverse events is Guillain-Barré syndrome.
Case Report:
Here, we describe a case of Guillain-Barré syndrome after the first dose of the BNT162b2 mRNA COVID-19 vaccine and review the literature to increase the current knowledge regarding this complication.
Conclusion:
Guillain-Barré syndrome after COVID-19 vaccination is responsive to treatment. The benefits of administering the vaccine outweigh the risks. Due to the negative impact of COVID-19, it is essential to recognize the development of neurological complications that are potentially associated with vaccination, including Guillain-Barré syndrome.
Insights
Guillain-Barré syndrome is a rare neurological complication that can occur after the BNT162b2 mRNA COVID-19 vaccine. Early recognition and treatment are crucial for recovery, and vaccine benefits outweigh risks.
Area of Science:
- Neurology
- Vaccinology
- Infectious Diseases
Background:
- The COVID-19 pandemic necessitated rapid vaccine development.
- Vaccines, including mRNA vaccines, can rarely cause neurological adverse events.
- Guillain-Barré syndrome is a potential neurological complication associated with vaccination.
Observation:
- A case of Guillain-Barré syndrome following the first dose of the BNT162b2 mRNA COVID-19 vaccine is presented.
- Literature review was conducted to understand this rare complication.
Findings:
- Guillain-Barré syndrome post-vaccination is treatable.
- Neurological complications, such as Guillain-Barré syndrome, require prompt identification.
Implications:
- Recognizing Guillain-Barré syndrome is essential for managing post-vaccination complications.
- The benefits of COVID-19 vaccination significantly outweigh the identified risks.
- This case contributes to the understanding of rare neurological events following mRNA vaccination.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
00:42Cross-reactivity
01:51Vaccinations
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...